01 / PROFILE
Peptide Profiles
Each entry explains what the peptide is, why people search for it, the proposed mechanism, and where the evidence stops.
Hype, hope, or real? Side-by-side: what the internet is claiming, what the evidence backs up, and whether it’s worth your money.
Educational reference. Not medical advice.
Reality checks
PT-141 has been FDA-approved since 2019 as Vyleesi — and the 2026 compounding wave that reshaped peptide access did not change that.
The amylin analog inside Novo Nordisk's next weight-loss drug just showed up in the NEJM at ADA 2026 — and it's not semaglutide.
TB-500 is on the July 23 FDA compounding docket — and the oral comment window closes in three days with the recovery claims still unproven.
The ACTH-fragment peptide from Russia just made the FDA's July 24 compounding docket — and the committee is reviewing a pharmacy-access question, not a cognitive-enhancement claim.
The mitochondrial peptide trending as exercise-in-a-vial just made the FDA's July 23 agenda — but regulators are asking about obesity and osteoporosis, not athletic optimization.
Sermorelin survived the 2023 compounding crackdown by not being on the restricted list. In 2026, new FDA attestation rules found it anyway.
Search the index
How we cut through the noise
01 / PROFILE
Each entry explains what the peptide is, why people search for it, the proposed mechanism, and where the evidence stops.
02 / NEWS
Clickbait headlines with real receipts. Daily article on a trending peptide — what people are claiming, what the evidence actually shows, where the line is.
03 / SAFETY
Profiles include risks, unknowns, approval context, and clear boundaries around dosing, sourcing, and personal medical advice.
04 / CATEGORY
Compare fitness and recovery, GLP-1 and metabolic, longevity and skin, endogenous biology, and approved clinical peptides.
Should you take it?
PeptideFactCheck separates approved use, human signal, early research, preclinical biology, anecdotes, and unknowns so curiosity does not become fake certainty.
Why you can trust the verdicts
IUPHAR/BPS, PubChem, UniProt, RCSB PDB, PubMed, Europe PMC, and ClinicalTrials.gov are used for molecular and research context.
FDA Orange Book, DailyMed, openFDA, and FDA safety communications are used for U.S. regulatory and label context.
Vendor pages, forum posts, and clinic claims can explain public interest, but they are not treated as authoritative evidence.